Related Experiment Videos
Pharmacokinetics of pipecuronium in infants, children and adults
E Tassonyi1, J F Pittet, C N Schopfer
1Department of Anesthesiology, University Hospital of Geneva, Switzerland.
Insights
Pipecuronium
Area of Science:
- Pharmacology
- Pediatric Anesthesiology
Background:
- Pipecuronium's clinical action duration varies by age.
- Infants show shorter duration than children or adults.
- Understanding age-related pharmacokinetic differences is crucial.
Purpose of the Study:
- To compare pipecuronium's pharmacokinetic profiles in infants, children, and adults.
- To elucidate age-dependent factors influencing pipecuronium's action.
- To explain observed differences in clinical duration of effect.
Main Methods:
- Pharmacokinetic analysis of pipecuronium in three age groups (infants, children, adults).
- Intravenous administration of equipotent doses (2 x ED95) of pipecuronium.
- Blood sampling for 4-5 hours post-injection, with quantification via radiolabeled rose bengal.
Main Results:
- Faster distribution half-life of pipecuronium in infants and children compared to adults.
- Significantly decreased plasma clearance in infants versus children and adults.
- Similar total volume of distribution across all age groups.
Conclusions:
- Pipecuronium pharmacokinetics are age-dependent, with faster distribution in younger groups and slower elimination in infants.
- Observed pharmacokinetic profiles do not explain faster infant recovery from neuromuscular blockade.
- Infants require careful pipecuronium dosage monitoring due to low plasma clearance to prevent prolonged paralysis.
Abstract:
In order to explain the reported shorter clinical duration of action of cumulative ED95 of pipecuronium in infants as compared to children or adults, the pharmacokinetic profiles of pipecuronium were compared in infants (n = 6; mean age 6.8 months; mean weight 7.3 kg) in children (n = 6; mean age 4.6 years; mean weight 19.2 kg) and in adults (n = 7; mean age 42 years; mean weight 58.2 kg). Equipotent doses (2 x ED95) of pipecuronium were injected i.v. as single bolus and arterial blood was sampled for 4-5 h. Pipecuronium was quantified by complex formation with [125I]-labelled rose bengal. Pharmacokinetic parameters were calculated using a two-compartment open model. The median for the distribution half-life of pipecuronium was 2.54 min (interquartile range: 1.0-2.5 min) in infants and 2.04 min (0.26-2.04 min) in children; both were significantly shorter than in adults (5.75 [3.7-9.7] min). The plasma clearance of pipecuronium was significantly decreased in infants (1.50 [0.6-1.5] ml.min-1.kg-1; P < 0.05) as compared to children and adults (2.27 [0.88-2.27] and 2.45 [1.7-3.2] ml.min-1.kg-1, respectively). The total volume of distribution was similar in all three groups. We conclude that the pharmacokinetic features of pipecuronium are age-dependent: differences as compared to adults consisted of a faster distribution in both infants and children and a slower elimination in infants. The pharmacokinetic profile of pipecuronium does not explain the faster recovery from neuromuscular blockade in infants as compared to children. Because of the low total plasma clearance in infants, pipecuronium dosage should be carefully monitored to avoid accumulation and prolonged paralysis.